Bowman Cox
Executive Editor
Washington DC, USA
18+ years of experience
Bowman has followed various energy, environmental and health care sectors, writing news for pharmacists, chemists, engineers, lawyers and other professionals.He has moderated and presented at industry and journalism conferences, and has a background in product development, having helped launch publications, conferences and a journalism association.
Bowman has a passion for connecting with professional communities, discovering their truths, telling their stories and helping them learn from each other. Other passions: crowd sourcing, data mining, classic movies and working on his basketball game.
Pink Sheet
By Bowman Cox 27 Nov 2020
Just as they did during the heparin crisis a decade ago, pharmaceutical companies must coordinate on coronavirus, Rx-360 CEO says.
Topic Manufacturing Vaccines Coronavirus
Scrip
By Bowman Cox 07 Feb 2020
As coronavirus spreads into China’s manufacturing region, quarantines and travel restrictions challenge international flow of pharmaceuticals, ingredients and personnel.
Topic Coronavirus
Pink Sheet
By Bowman Cox 22 Aug 2018
When firms are developing highly anticipated gene therapies, it’s important to establish GMP-controlled manufacturing processes earlier in development, as Sarepta discovered when US FDA placed a clinical hold on a promising Duchenne muscular dystrophy gene therapy.
Topic FDA
Scrip
By Bowman Cox 23 Feb 2018
An FDA warning letter to a contract manufacturer, Pfizer, delayed Sandoz/Momenta's Glatopa 40 mg launch, reducing projected revenues and leading Momenta to consider selling assets.
Topic FDA Business Strategies
Pink Sheet
By Bowman Cox 24 Oct 2017
The race is on in Puerto Rico to avert critical drug shortages that could hit the US in a few months if service from the island's electrical grid hasn't been restored.
Topic BioPharmaceutical
Pink Sheet
By Bowman Cox 17 Jan 2017
Congressional oversight agency urges FDA to make better use of foreign offices with more effective performance measures and staffing goals; GAO notes agency’s progress towards risk-based inspections – and its plan to revisit every site at least once every five years.
Medtech Insight
25 Jul 2022
Medtech Insight
25 Jul 2022
HBW Insight
24 Jul 2022
Pink Sheet
22 Jul 2022
Generics Bulletin
13 Jul 2022
Pink Sheet
05 Jul 2022
Pink Sheet
30 Jun 2022
Pink Sheet
28 Jun 2022
Pink Sheet
24 Jun 2022
Pink Sheet
22 Jun 2022
Pink Sheet
13 Jun 2022
Pink Sheet
07 Jun 2022
Pink Sheet
03 Jun 2022
Pink Sheet
03 Jun 2022
Pink Sheet
31 May 2022